As of 3:27:48 PM EST. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 2 | 7 | 7 |
| Avg. Estimate | -0.31 | -0.22 | -0.69 | -1.26 |
| Low Estimate | -0.44 | -0.23 | -1.06 | -1.67 |
| High Estimate | -0.19 | -0.21 | -0.51 | -0.96 |
| Year Ago EPS | -0.33 | -0.03 | -1.3 | -0.69 |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 2 | 7 | 7 |
| Avg. Estimate | 16.16M | 22.06M | 121.56M | 65.53M |
| Low Estimate | 12.3M | 21.1M | 117.28M | 44.27M |
| High Estimate | 21.46M | 23.01M | 126.16M | 94.9M |
| Year Ago Sales | 17.28M | 32.74M | 58.62M | 121.56M |
| Sales Growth (year/est) | -6.53% | -32.64% | 107.35% | -46.09% |
Earnings History
| Currency in USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.39 | -0.22 | -0.31 | -0.28 |
| EPS Actual | -0.33 | -0.03 | -0.19 | -0.08 |
| Difference | 0.07 | 0.19 | 0.12 | 0.19 |
| Surprise % | 16.97% | 85.28% | 39.17% | 69.36% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.31 | -0.22 | -0.69 | -1.26 |
| 7 Days Ago | -0.29 | -0.25 | -0.75 | -1.26 |
| 30 Days Ago | -0.35 | -0.27 | -0.89 | -1.3 |
| 60 Days Ago | -0.39 | -0.29 | -0.94 | -1.37 |
| 90 Days Ago | -0.37 | -0.29 | -0.91 | -1.3 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 3 | 1 | 7 | 4 |
| Up Last 30 Days | 3 | 1 | 7 | 4 |
| Down Last 7 Days | 2 | -- | -- | 2 |
| Down Last 30 Days | 2 | -- | -- | 2 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| IMTX | 4.41% | -581.05% | 46.97% | -82.44% |
| S&P 500 | 5.00% | 12.00% | 2.10% | 12.20% |
Upgrades & Downgrades
| Maintains | B of A Securities: Buy to Buy | 11/19/2024 |
| Initiated | Piper Sandler: Overweight | 10/7/2024 |
| Reiterates | Cantor Fitzgerald: Overweight | 9/9/2024 |
| Reiterates | Cantor Fitzgerald: Overweight | 9/5/2024 |
| Maintains | Mizuho: Buy to Buy | 5/16/2024 |
| Initiated | Cantor Fitzgerald: Overweight | 11/2/2023 |
Related Tickers
IMCR Immunocore Holdings plc
28.47
-1.52%
IDYA IDEAYA Biosciences, Inc.
25.91
+2.84%
TCRX TScan Therapeutics, Inc.
2.9950
+5.09%
NRIX Nurix Therapeutics, Inc.
21.02
+3.68%
ACRV Acrivon Therapeutics, Inc.
7.01
-0.78%
DAWN Day One Biopharmaceuticals, Inc.
12.66
-0.71%
IGMS IGM Biosciences, Inc.
7.27
+1.32%
PRAX Praxis Precision Medicines, Inc.
71.50
+1.88%
XNCR Xencor, Inc.
24.44
+1.69%
DNTH Dianthus Therapeutics, Inc.
23.82
+0.03%